Yuyang Sun

Bone-targeting engineered exosomes delivering teriparatide mRNA for the treatment of osteoporosis

Introduction Teriparatide (TPTD) is an established osteoanabolic agent for the treatment of osteoporosis; however, its short circulating half-life necessitates repeated administration, while limited skeletal selectivity may reduce delivery efficiency. To address these limitations...